SelonabantAlso known as ANEB-001
CB1 antagonist in development for acute cannabinoid intoxication; it reduced THC effects in a phase II trial in healthy volunteers.
C₂₂H₂₄ClF₃N₂O₂
CAS 791848-71-0
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 440.90 g/mol
Updated on
In plain terms
Selonabant is an experimental molecule that blocks the CB1 receptor, the one THC activates. In a 2025 trial in healthy volunteers who had been given THC, it markedly reduced the feeling of being « high » and postural instability. It is not authorised as a medicine.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to Selonabant: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Selonabant.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Antagonistno measured value cited
functional antagonism demonstrated in humans: feeling high reduced by up to 82.8% at 30 mg (Gorbenko et al. 2025); no affinity constant found
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of Selonabant, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
Selonabant, first studied for obesity, is being developed under the code ANEB-001 for a different aim: acute cannabinoid intoxication. Gorbenko and colleagues recall that emergency department visits for cannabinoid-related toxicity have increased worldwide as more states have liberalised cannabis policy, with symptoms such as anxiety, panic attacks, tachycardia and psychosis, mainly mediated by CB1 agonism by Δ9-THC. Their phase II trial (randomised, double-blind, placebo-controlled, in healthy adults) combines oral THC (10.5 mg, then 21 mg) with oral selonabant capsules (10, 30, 50 or 100 mg). Versus placebo, selonabant reduced feeling high by up to 82.8 % at 30 mg, increased self-reported alertness by up to 10.8 mm, and reduced postural instability by up to 30.6 % at 30 mg; heart rate was not significantly changed. The product was judged generally safe, with no clinically meaningful change in mood; nausea and vomiting were more frequent at high doses, and the 10-mg dose was both well tolerated and efficacious. The authors conclude that these results support further development for emergency treatment of acute cannabinoid intoxication (Gorbenko et al. 2025). The trial was funded by Anebulo Pharmaceuticals, several of whose shareholders or executives are among the authors.
Key sources.
- Gorbenko et al., Clin Pharmacol Ther 2025: the CB1 antagonist selonabant (ANEB-001) blocks the acute effects of THC in healthy volunteers, a randomised controlled phase II trial (new tab)PMID 39898464
- Janero and Makriyannis, Expert Opin Emerg Drugs 2009: cannabinoid receptor antagonists (cites V24343 among the agents studied clinically) (new tab)PMID 19249987
- PubChem, selonabant, CID 68902536 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound with no known natural occurrence. It is in clinical development (phase II published in 2025) and is not marketed.
Origin
Research tool
No known biosynthetic pathway: a synthetic molecule. It is an azetidine carboxamide, N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide (name read on PubChem, CID 68902536).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. The compound is in clinical development and no marketing authorisation was found.
- France
Not classified: selonabant does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (an azetidine carboxamide benzhydryl ether) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). The compound is in clinical development; no marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Gorbenko et al., Clin Pharmacol Ther 2025: the CB1 antagonist selonabant (ANEB-001) blocks the acute effects of THC in healthy volunteers, a randomised controlled phase II trial (new tab)PMID 39898464
- Janero and Makriyannis, Expert Opin Emerg Drugs 2009: cannabinoid receptor antagonists (cites V24343 among the agents studied clinically) (new tab)PMID 19249987
- PubChem, selonabant, CID 68902536 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- Common name
- Selonabant (ANEB-001)
- IUPAC name
- N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide
- Other names
- ANEB-001 · ANEB 001 · Selonabant · V-24343
Identifiers
- Formula
- C₂₂H₂₄ClF₃N₂O₂
- CAS
- 791848-71-0
- PubChem CID
- 68902536(new tab)
- InChIKey
- BNLYOVHLLDBOFZ-LJQANCHMSA-N
- SMILES
- CC(C)
(C) NC(= O) N1CC(O[C@H] (c2ccc(Cl) cc2) c2ccccc2C(F) (F) F) C1
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.